The other limitation of our study lies in the heterogeneity of the psoriasis clinical phenotypes described in our patients that may explain the lack of association between HLA-C alleles and disease severity; MTX treatment outcome could also be assessed. The gene discussed is HLA-C; the disease is psoriasis.